IMVT-1401-2401
Gratis
2.12.7 (33)for iPhone, iPad and more
Age Rating
IMVT-1401-2401 Screenshots
About IMVT-1401-2401
The Immunovant eCOA App is intended for use to collect weekly study dosing information in a dosing diary relating to the IMVT-1401-2401 clinical trial. Patients must be given accounts by a participating site in order to log in to the app.
Show More
Was ist neu in der neuesten Version 2.12.7 (33)
Last updated on Mar 27, 2024
Alte Versionen
1) Cohort C eligibility message and functionality during Screening Visit and Visit 13 have been updated per latest protocol.
Inclusion Criteria: Patients have an INCAT score of ≥ 2 points at the Screening and Period 1 Baseline Visits. Note: Participants with an INCAT score of 2 at study entry must have this score exclusively from the leg disability score; for participants with an INCAT score of ≥ 3 at study entry, there are no specific requirements for arm or leg.
2) Site has the ability to make a decision to discontinue the patient from study treatment at the end of any visit if the patient chooses to, regardless of worsening or relapse status, and based on that decision the Clario system will either move the patient to Follow up or the appropriate Early Termination Phase, dependent upon the current visit and whether all Early Termination forms have been completed.
3) Joing Blinded assessor & C-SSRS rater role has been removed from tablet setup.
4) INCAT Score Check Form added in all Visits of Period 1 to monitor Worsening.
Inclusion Criteria: Patients have an INCAT score of ≥ 2 points at the Screening and Period 1 Baseline Visits. Note: Participants with an INCAT score of 2 at study entry must have this score exclusively from the leg disability score; for participants with an INCAT score of ≥ 3 at study entry, there are no specific requirements for arm or leg.
2) Site has the ability to make a decision to discontinue the patient from study treatment at the end of any visit if the patient chooses to, regardless of worsening or relapse status, and based on that decision the Clario system will either move the patient to Follow up or the appropriate Early Termination Phase, dependent upon the current visit and whether all Early Termination forms have been completed.
3) Joing Blinded assessor & C-SSRS rater role has been removed from tablet setup.
4) INCAT Score Check Form added in all Visits of Period 1 to monitor Worsening.
Show More
Version History
2.12.7 (33)
Mar 27, 2024
1) Cohort C eligibility message and functionality during Screening Visit and Visit 13 have been updated per latest protocol.
Inclusion Criteria: Patients have an INCAT score of ≥ 2 points at the Screening and Period 1 Baseline Visits. Note: Participants with an INCAT score of 2 at study entry must have this score exclusively from the leg disability score; for participants with an INCAT score of ≥ 3 at study entry, there are no specific requirements for arm or leg.
2) Site has the ability to make a decision to discontinue the patient from study treatment at the end of any visit if the patient chooses to, regardless of worsening or relapse status, and based on that decision the Clario system will either move the patient to Follow up or the appropriate Early Termination Phase, dependent upon the current visit and whether all Early Termination forms have been completed.
3) Joing Blinded assessor & C-SSRS rater role has been removed from tablet setup.
4) INCAT Score Check Form added in all Visits of Period 1 to monitor Worsening.
Inclusion Criteria: Patients have an INCAT score of ≥ 2 points at the Screening and Period 1 Baseline Visits. Note: Participants with an INCAT score of 2 at study entry must have this score exclusively from the leg disability score; for participants with an INCAT score of ≥ 3 at study entry, there are no specific requirements for arm or leg.
2) Site has the ability to make a decision to discontinue the patient from study treatment at the end of any visit if the patient chooses to, regardless of worsening or relapse status, and based on that decision the Clario system will either move the patient to Follow up or the appropriate Early Termination Phase, dependent upon the current visit and whether all Early Termination forms have been completed.
3) Joing Blinded assessor & C-SSRS rater role has been removed from tablet setup.
4) INCAT Score Check Form added in all Visits of Period 1 to monitor Worsening.
2.12.6 (27)
Nov 22, 2023
updated Brazil dosing diary and released batch 6
2.12.5 (23)
Sep 13, 2023
Language Update
2.12.4 (20)
Jun 5, 2023
Language update
2.12.3 (16)
May 16, 2023
Added the below languages:
Polish (Poland)
Spanish (United States)
Spanish (Spain)
Catalan (Spain)
Italian (Italy)
Polish (Poland)
Spanish (United States)
Spanish (Spain)
Catalan (Spain)
Italian (Italy)
2.12.2 (13)
Apr 25, 2023
Language update
2.12.1 (10)
Apr 7, 2023
IMVT-1401-2401 FAQ
Klicken Sie hier, um zu erfahren, wie Sie IMVT-1401-2401 in eingeschränkten Ländern oder Regionen herunterladen können.
Überprüfen Sie die folgende Liste, um die Mindestanforderungen von IMVT-1401-2401 zu sehen.
iPhone
Erfordert iOS 12.0 oder neuer.
iPad
Erfordert iPadOS 12.0 oder neuer.
iPod touch
Erfordert iOS 12.0 oder neuer.
IMVT-1401-2401 unterstützt Englisch